Laboratory handling and histology reporting of breast specimens from patients who have received neoadjuvant chemotherapy

Neoadjuvant chemotherapy is increasingly being offered to patients with invasive breast carcinoma but surgical excision specimens following such therapy may be difficult to interpret in the pathology laboratory, both macroscopically and histologically. We provide here some guidelines for handling such postneoadjuvant chemotherapy samples and describe the histopathological features which may be encountered in both the breast and lymph nodes received. We also present a brief review of the literature and suggest a simple method for quantifying the degree of response to neoadjuvant chemotherapy in both the primary breast carcinoma and the lymph nodes.

[1]  A. Makris,et al.  Evaluation of ER, PgR, HER-2 and Ki-67 as predictors of response to neoadjuvant anthracycline chemotherapy for operable breast cancer , 2004, British Journal of Cancer.

[2]  F. Penault-Llorca,et al.  Prognostic significance of a complete pathological response after induction chemotherapy in operable breast cancer , 2002, British Journal of Cancer.

[3]  P. Hurteloup,et al.  Inflammatory Breast Cancer: Pilot Study of Intensive Induction Chemotherapy (FEC‐HD) Results in a High Histologic Response Rate , 1993 .

[4]  R. Hildenbrand,et al.  HER2/neu, p53, Ki67, and hormone receptors do not change during neoadjuvant chemotherapy in breast cancer , 2005, Virchows Archiv.

[5]  G. Hortobagyi,et al.  Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  S. Al-Sobhi,et al.  Decreased axillary lymph node retrieval in patients after neoadjuvant chemotherapy. , 2002, American journal of surgery.

[7]  A. Luini,et al.  Primary chemotherapy to avoid mastectomy in tumors with diameters of three centimeters or more. , 1990, Journal of the National Cancer Institute.

[8]  F. Penault-Llorca,et al.  Prognostic Value of Residual Node Involvement in Operable Breast Cancer after Induction Chemotherapy , 2002, Breast Cancer Research and Treatment.

[9]  F. Penault-Llorca,et al.  Is Nottingham prognostic index useful after induction chemotherapy in operable breast cancer? , 2003, British Journal of Cancer.

[10]  Z. Baloch,et al.  Pathologic response to induction chemotherapy in locally advanced carcinoma of the breast: a determinant of outcome. , 1995, Journal of the American College of Surgeons.

[11]  Fiona J Gilbert,et al.  Neoadjuvant chemotherapy in breast cancer: significantly enhanced response with docetaxel. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  G. Hortobagyi,et al.  Predictors of locoregional recurrence in patients with locally advanced breast cancer treated with neoadjuvant chemotherapy, mastectomy, and radiotherapy. , 2005, International journal of radiation oncology, biology, physics.

[13]  A. Miller,et al.  Reporting results of cancer treatment , 1981, Cancer.

[14]  J. Pierga,et al.  Prognostic factors for survival after neoadjuvant chemotherapy in operable breast cancer. the role of clinical response. , 2003, European journal of cancer.

[15]  C. Sung,et al.  Her-2/neu expression in locally advanced breast carcinomas: pre- and post-neoadjuvant chemotherapy , 2005, Breast Cancer.

[16]  B. Cady,et al.  The effect of neoadjuvant chemotherapy on estrogen and progesterone receptor expression and hormone receptor status in breast cancer. , 2003, American journal of surgery.

[17]  L. Newman,et al.  Histopathologic Evidence of Tumor Regression in the Axillary Lymph Nodes of Patients Treated With Preoperative Chemotherapy Correlates With Breast Cancer Outcome , 2003, Annals of Surgical Oncology.

[18]  M. Brizzi,et al.  Effect of neoadjuvant chemotherapy on Ki67 labelling index, c-erbB-2 expression and steroid hormone receptor status in human breast tumours. , 1996, Anticancer research.

[19]  A. Satterfield,et al.  TREATMENT , 1924, California and western medicine.

[20]  I. Ellis,et al.  The Nottingham prognostic index in primary breast cancer , 2005, Breast Cancer Research and Treatment.

[21]  A. Schneeweiss,et al.  Only grading has independent impact on breast cancer survival after adjustment for pathological response to preoperative chemotherapy , 2004, Anti-cancer drugs.

[22]  Carder Typing breast cancer following primary chemotherapy , 1999, Histopathology.

[23]  T E Walsh,et al.  Reporting results. , 1969, Archives of otolaryngology.